WO2017213247A1 - 心疾患の非侵襲的画像診断剤 - Google Patents
心疾患の非侵襲的画像診断剤 Download PDFInfo
- Publication number
- WO2017213247A1 WO2017213247A1 PCT/JP2017/021442 JP2017021442W WO2017213247A1 WO 2017213247 A1 WO2017213247 A1 WO 2017213247A1 JP 2017021442 W JP2017021442 W JP 2017021442W WO 2017213247 A1 WO2017213247 A1 WO 2017213247A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- heart disease
- compound
- hydrogen atom
- imaging agent
- diagnostic imaging
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Definitions
- the present invention relates to a noninvasive diagnostic imaging agent for heart disease.
- RAAS renin-angiotensin-aldosterone system
- Non-Patent Document 1 describes that blood collected by cardiac catheterization showed that aldosterone was synthesized and secreted in a human failing heart.
- Non-Patent Document 2 reveals that the gene expression of CYP11B2, which is an aldosterone synthase, is enhanced by examination using an autopsy heart. And it has been shown that this increased expression of CYP11B2 gene is associated with myocardial fibrosis and cardiac dysfunction.
- Non-Patent Document 6 Although not intended for cardiovascular disease, various radioactive compounds having high selectivity for CYP11B2 have been developed for the purpose of depicting the lesions of the adrenal glands and enabling imaging diagnosis of primary aldosteronism ( (Patent Documents 4 to 11, Non-Patent Document 6)
- Detecting the expression of CYP11B2 in the heart may lead to the evaluation of the progression of heart diseases such as heart failure.
- heart diseases such as heart failure.
- non-invasive methods that can detect these lesions.
- Nuclear medicine diagnosis using single photon tomography (SPECT) and positron emission tomography (PET) is one of the methods for detecting changes in the molecular level in vivo.
- Patent Documents 4 to 11 and Non-Patent Document 6 report a SPECT or PET tracer showing high selectivity for CYP11B2, but these are targeted to the adrenal gland and are suitable for imaging in the heart. It is not clear whether it is.
- the present invention has been made in view of the above circumstances, and provides a technique for noninvasively detecting a lesion of a heart disease.
- a noninvasive diagnostic imaging agent for heart disease containing a radiolabeled compound having a binding ability to aldosterone synthase or a salt thereof as an active ingredient.
- FIG. 1 is the figure which arranged the autoradiogram of each section toward the apex part from the base of the heart, (b) after rotating the autoradiogram surrounded by the broken line in (a) 90 degrees.
- FIG. It is a figure which shows the dyeing
- (A) is a figure which shows the result of HE dyeing
- (b) is a figure which shows the result of Masson trichrome dyeing
- (c) is a figure which shows the result of immunostaining of CYP11B2.
- FIG. 6 shows the results of immersion in a solution containing (-ylmethyl) pyridin-3-yl] benzimidazole (compound [ 18 F] 1).
- (E) shows a normal rat heart tissue section treated with 6-chloro-5-fluoro-1- (2- [ 18 F] fluoroethyl) -2- [5- (imidazol-1-ylmethyl) pyridin-3-yl.
- FIG. 6 is a diagram showing the result of immersion in a liquid containing -yl] benzimidazole (Compound 1).
- FIG. 3 is a view showing a result of immersion in a liquid containing (-1-ylmethyl) pyridin-3-yl] benzimidazole (Compound 1).
- FIG. 1 shows a heart tissue section of an ischemic heart disease model rat obtained from 1- (2-fluoroethyl) -2- [5- ⁇ (imidazol-1-yl) methyl ⁇ pyridin-3-yl] -6- [ 123 I] iodo-benzimidazole (compound [123 I] 2) is a diagram showing a result of the immersion in a liquid containing.
- (C) shows normal rat heart tissue sections treated with 1- (2-fluoroethyl) -2- [5- ⁇ (imidazol-1-yl) methyl ⁇ pyridin-3-yl] -6- [ 123 I] iodo Benzimidazole (compound [ 123 I] 2) and 5 ⁇ mol / L 1- (2-fluoroethyl) -2- [5- ⁇ (imidazol-1-yl) methyl ⁇ pyridin-3-yl] -6- It is a figure which shows the result immersed in the liquid containing iodobenzimidazole (compound 2).
- FIG. 6 is a diagram showing the results of immersion in a liquid containing 6-iodobenzimidazole (Compound 2).
- (A) represents 6-chloro-5-fluoro-1- (2- [ 18 F] fluoroethyl) -2- [5- (imidazol-1-ylmethyl) pyridin-3-yl] benzimidazole (compound [ 18 F] It is a figure which shows the example of ROI (Region of Interest; Region of Interest) set on the autoradiogram of the slice immersed in the liquid containing 1).
- (B) represents 6-chloro-5-fluoro-1- (2- [ 18 F] fluoroethyl) -2- [5- (imidazol-1-ylmethyl) pyridin-3-yl] benzimidazole (compound [ 18 F]
- (C) represents 1- (2-fluoroethyl) -2- [5- ⁇ (imidazol-1-yl) methyl ⁇ pyridin-3-yl] -6- [ 123 I] iodobenzimidazole (compound [ 123 I ] It is a figure which shows the example of ROI set on the autoradiogram of the slice immersed in the liquid containing 2).
- (D) represents 1- (2-fluoroethyl) -2- [5- ⁇ (imidazol-1-yl) methyl ⁇ pyridin-3-yl] -6- [ 123 I] iodobenzimidazole (compound [ 123 I ] Is a graph showing the ratio of the signal intensity at the ischemia / reperfusion site / the signal intensity at the non-ischemic site in 2) as a bar graph for each individual.
- FIG. 3 shows the results of autoradiography and staining of -3-yl] -6- [ 123 I] iodobenzimidazole (compound [ 123 I] 2).
- (A) is a graph showing the signal intensity ratio of ischemia / reperfusion site / non-ischemic site as a bar graph, and
- (b) is a diagram showing the results of Masson trichrome staining.
- FIG. 2- [5- ⁇ (1H-imidazol-1-yl) methyl ⁇ pyridin-3-yl] -6- [ 123 I] iodo-1-methyl-1H-benzo [d] imidazole (compound [ 123 I] 3 ) Shows the results of in vitro autoradiography.
- (A) is a figure which shows the result of the autoradiography of the heart tissue section of a normal rat
- (b) is a figure which shows the result of the autoradiography of the heart tissue section of a myocarditis model rat
- (c ) Is a diagram showing the results of Masson trichrome staining of heart tissue sections of normal rats
- (d) is a diagram showing the results of Masson trichrome staining of heart tissue sections of myocarditis model rats
- (E) is a figure which shows the result of the CYP11B2 immunostaining of the heart tissue section of a normal rat
- (f) is a figure which shows the result of the immunostaining of CYP11B2 of the heart tissue section of a myocarditis model rat.
- FIG. 1 It is a figure which shows the result of the immunostaining of CYP11B2 using each heart tissue section of a hypertensive heart disease model rat and a normal rat.
- A is an overall view of a heart tissue section of a hypertensive heart disease model
- (b) is an enlarged view of (a)
- (c) is an overall view of a heart tissue section of a normal rat
- (d ) Is an enlarged view of (c).
- FIG. 1 is a diagram showing the results of autoradiography of heart tissue sections of normal rats
- (b) is a diagram showing the results of autoradiography of heart tissue sections of hypertensive heart disease model rats
- C is a figure which shows the result of Masson trichrome staining of the heart tissue section of a normal rat
- (d) is the result of Masson trichrome staining of the heart tissue section of a hypertensive heart disease model rat
- E is a diagram showing the results of CYP11B2 immunostaining of heart tissue sections of normal rats
- (f) is the results of CYP11B2 immunostaining of heart tissue sections of hypertensive heart disease model rats.
- FIG. B shows a heart tissue section of an ischemic heart disease model rat 2- [5- ⁇ (1H-imidazol-1-yl) methyl ⁇ pyridin-3-yl] -6- [ 123 I] iodo-1- It is a figure which shows the result of being immersed in the liquid containing methyl-1H-benzo [d] imidazole (compound [ 123I ] 3).
- the present invention is a noninvasive diagnostic imaging agent for heart disease containing a radiolabeled compound or a salt thereof capable of binding to aldosterone synthase as an active ingredient. According to the diagnostic imaging agent of the present invention, it is possible to depict a site where the fibrosis of the heart is progressing.
- the “noninvasive diagnostic imaging agent” is used for nuclear medicine diagnosis, and preferably used for positron emission tomography (PET) or single photon tomography (SPECT).
- PET positron emission tomography
- SPECT single photon tomography
- the “heart disease” includes ischemic heart disease and non-ischemic heart disease, preferably a disease caused by fibrosis of the heart, and an example is heart failure.
- the “ischemic heart disease” is not limited as long as it is a heart disease caused by myocardial ischemia, and examples thereof include coronary heart disease angina, myocardial infarction, acute coronary syndrome, ischemic heart failure and the like.
- non-ischemic heart disease includes myocarditis, hypertensive heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathy, non-ischemic heart failure, and the like.
- the “radiolabeled compound” is not limited as long as it is a compound labeled with a radioisotope used in nuclear medicine diagnosis.
- the radioisotope include carbon-11, fluorine-18, chlorine-34m, bromine-76, iodine-123, and iodine-124.
- the noninvasive diagnostic imaging agent of the present invention is a diagnostic imaging agent for positron emission tomography when a positron emitting nuclide such as carbon-11, fluorine-18, chlorine-34m, iodine-124 is used as a radioisotope.
- iodine-123 is used as the radioactive halogen atom, it can be used as an image diagnostic agent for single photon tomography.
- “having binding ability to aldosterone synthase” means having binding ability to human CYP11B2.
- the “radiolabeled compound having binding ability to aldosterone synthase” is not limited as long as it has binding ability to human CYP11B2, and for example, US Application Publication No. 2005/0033060, Special Table 2009- Radiolabeled compounds having affinity for adrenal cortical adenoma and adrenal cortex cancer described in Japanese Patent No. 539822, JP 2013-534911 A, JP 2014-129315 A, JP 2015-009831, A Examples of radiolabeled compounds having CYP11B2 selectivity described in Japanese Patent Application Laid-Open Nos. 2015-0093832, 2015-093833, 2015-110563, 2015-193545, and International Publication No. 2015/199205. It is done.
- One of the constituent elements of the compounds described in JP-T-2014-527077 and JP-T-2014-533736 may be replaced with the aforementioned radioisotope.
- a preferred radiolabeled compound in the present invention is represented by the following general formula (1) described in the pamphlet of International Publication No. 2015/199205.
- R 1 represents a hydrogen atom or CO 2 R a.
- R 2 represents a hydrogen atom, a halogen atom or a CO 2 R a.
- R 3 represents a hydrogen atom or a hydroxyalkyl group having 1 to 10 carbon atoms.
- R 4 represents a hydrogen atom, a hydroxy group or an alkoxy group having 1 to 10 carbon atoms.
- R 5 represents a chain alkyl group having 1 to 5 carbon atoms in which a hydrogen atom may be substituted with a halogen atom, or a cyclic alkyl group having 3 to 5 carbon atoms in which a hydrogen atom may be substituted with a halogen atom.
- A represents CH or a nitrogen atom.
- X 1 and X 3 each independently represent a hydrogen atom or a halogen atom.
- X 2 represents a hydrogen atom, a halogen atom or a nitrile group, and at least one of X 1 , X 2 and X 3 is a halogen atom.
- “CO 2 R a ” is a carboxylic acid ester group.
- Each R a is independently an alkyl group having 1 to 10 carbon atoms, and the alkyl group may be linear or branched, but preferably an alkyl group having 1 to 5 carbon atoms.
- Alkyl group (methyl group, ethyl group, n-propyl group, isopropyl group).
- “CO 2 R a ” is particularly preferably a “carboxylic acid methyl ester group” in which R a is a methyl group.
- the “halogen atom” is a fluorine atom, a chlorine atom, a bromine atom or an iodine atom.
- the “hydroxyalkyl group” is a group represented by — (CH 2 ) m OH.
- m is an integer of 1 to 10, preferably an integer of 1 to 3.
- R 5 m is an integer of 1 to 5, but is preferably an integer of 1 to 3.
- the “alkoxy group” is a group in which a linear or branched alkyl group is bonded to an oxygen atom, preferably a methoxy group, an ethoxy group, or a propoxy group. And an isopropoxy group, and a methoxy group is more preferable.
- the “chain alkyl group” is an acyclic alkyl group, which may be linear or branched, preferably a methyl group, Examples thereof include an ethyl group, a propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a neopentyl group, and a tert-pentyl group.
- one or two or more hydrogen atoms may be substituted with halogen atoms, and are preferably substituted with fluorine atoms.
- Specific examples include a fluoromethyl group, a 1-fluoroethyl group, a 1,1-difluoroethyl group, a 1,1,1-trifluoroethyl group, and a 1-fluoropropyl group.
- examples of the “cyclic alkyl group” include a cyclopropyl group, a cyclobutyl group, and a cyclopentyl group.
- these cyclic alkyl groups one or two or more hydrogen atoms may be substituted with a halogen atom.
- the “halobenzyl group” in the radiolabeled compound of the general formula (1) is a compound in which a hydrogen atom at the 2-position, 3-position or 4-position of the benzene ring of the benzyl group is substituted with a halogen atom.
- the one in which the hydrogen atom at the position is substituted with a halogen atom is an o-halobenzyl group
- the one in which the hydrogen atom at the 3-position is substituted with a halogen atom is an m-halobenzyl group
- the hydrogen atom at the 4-position is a halogen atom.
- the one substituted with an atom is a p-halobenzyl group. Of these, a p-halobenzyl group is preferable.
- the radiolabeled compound of the above general formula (1) is one in which any one of R 2 , R 5 , or X 2 contains a radiohalogen atom.
- a radioactive halogen atom used in the R 2 halogen atoms is a group represented by — (CH 2 ) n X 4 , and a radioactive halogen atom is used as the halogen atom for X 4 .
- R 5 is a p-halobenzyl group, and a radioactive halogen atom is used as the halogen atom introduced at the 4-position of the benzyl group. Radioactive halogen atom is used as (d) a halogen atom X 2.
- radioactive halogen atom refers to any of fluorine-18, chlorine-34m, bromine-76, iodine-123 or iodine-124.
- R 3 is a hydrogen atom
- R 4 is a hydrogen atom or an alkoxy group having 1 to 10 carbon atoms
- R 5 is a hydrogen atom substituted with a halogen atom.
- X 2 is a halogen atom
- X 3 is hydrogen. Is an atom.
- R 5 is more preferably a methyl group, an ethyl group, a propyl group, an isopropyl group, — (CH 2 ) n X 4 (where n represents an integer of 1 to 5, and X 4 represents a halogen atom). Or a cyclopropyl group or a p-halobenzyl group.
- R 2 is a hydrogen atom or a halogen atom.
- R 5 is a methyl group, an ethyl group, a group represented by — (CH 2 ) n X 4 , or a cyclopropyl group.
- n is preferably an integer of 1 to 3, more preferably 2 or 3, and still more preferably 2.
- X 4 is preferably a fluorine atom.
- One specific embodiment of the compound according to the present invention includes a compound represented by the general formula (2).
- R 12 is a hydrogen atom, a halogen atom or a CO 2 R a
- X 11 represents a hydrogen atom or a halogen atom
- X 12 represents a halogen atom
- X 14 is a hydrogen atom Represents a halogen atom or a hydroxy group
- n represents an integer of 1 to 5.
- “CO 2 R a ” has the same definition as in the general formula (1).
- R 1 is a hydrogen atom
- R 2 is a hydrogen atom, a halogen atom, or CO 2 R a (where R a has 1 carbon atom)
- R a has 1 carbon atom
- An alkyl group having ⁇ 10, R 3 and R 4 are hydrogen atoms
- R 5 is a chain alkyl group having 1 to 5 carbon atoms or a group represented by — (CH 2 ) n X 14
- A is CH
- X 1 is a hydrogen atom or a halogen atom
- X 2 is a halogen atom
- X 3 is a hydrogen atom.
- R 12 is also good as a hydrogen atom or CO 2 R a
- hydrogen atom is preferable.
- X 14 is preferably a hydrogen atom or a fluorine atom
- n is preferably an integer of 1 to 3.
- R 12 , X 12 , or X 14 is a radioactive halogen atom, preferably X 12 or X 14 is a radioactive halogen atom, and R 12 is a hydrogen atom, More preferably, X 12 or X 14 is a radioactive halogen atom.
- n is still more preferably an integer of 1 to 3.
- the definition of a radioactive halogen atom is synonymous with the above-mentioned definition.
- the compounds represented by the above general formulas (1) and (2) can be obtained by the method described in International Publication No. 2015/199205 pamphlet.
- the “salt” may be any one that is pharmaceutically acceptable.
- inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, or acetic acid, trifluoroacetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycol Acid, salicylic acid, pyranosidic acid (glucuronic acid, galacturonic acid, etc.), ⁇ -hydroxy acid (citric acid, tartaric acid, etc.), amino acid (aspartic acid, glutamic acid, etc.), aromatic acid (benzoic acid, cinnamic acid, etc.), sulfone Salts derived from organic acids such as acids (p-toluenesulfonic acid, ethanesulfonic acid, etc.) can be used.
- the noninvasive diagnostic imaging agent of the present invention is a formulation containing the above-mentioned radiolabeled compound or a salt thereof in a form suitable for administration into a living body.
- This non-invasive diagnostic imaging agent is preferably administered parenterally, that is, by injection, and more preferably an aqueous solution.
- Such compositions may optionally contain additional components such as pH adjusters, pharmaceutically acceptable solubilizers, stabilizers or antioxidants.
- Compound 1 was synthesized according to the synthesis method of Compound 100 in International Publication No. 2015/199205 pamphlet.
- Compound [ 18 F] 1 was synthesized according to the synthesis method of compound [ 18 F] 100 of International Publication No. 2015/199205 pamphlet, and used with a radiochemical purity of 95% or more under the TLC conditions disclosed in the same document.
- Compound 2 was synthesized according to the synthesis method of Compound 604 in International Publication No. 2015/199205.
- For compound [123 I] 2 were synthesized according to WO 2015/199205 pamphlet of Compound [123 I] 604 synthesis of, was used radiochemical purity of 95% or more by TLC under the conditions of the disclosure.
- Compound 3 was synthesized according to the synthesis method of compound 607 in International Publication No. 2015/199205 pamphlet.
- Compound [ 123 I] 3 was synthesized according to the synthesis method of compound [ 123 I] 607 in International Publication No. 2015/199205 pamphlet, and used with a radiochemical purity of 95% or more under the TLC conditions disclosed in the same document.
- Example 1 Evaluation of CYP11B2 expression in the heart of a rat model of ischemic heart disease
- a Wistar rat male was thoracotomized under isoflurane anesthesia, the left coronary artery was ligated for 30 minutes, reperfused, closed, and ischemic A heart disease model rat was prepared. About one week after the operation, the rats were sacrificed under anesthesia, the heart was taken out, and a 5 ⁇ m-thick section was prepared from the base of the heart. Using the prepared sections, immunostaining was performed to confirm the expression and distribution of CPY11B2.
- the anti-CYP11B2 antibody was prepared according to the method described in Ogishima T et al, Endocrinology, 1992, vol. 130, pp.2971-7, and the secondary antibody was HRP Labeled Polymer Anti-Rabbit (manufactured by Dako). Was used.
- the CYP11B2 expression site was detected by applying DAB + (3,3′-diaminobenzidine tetrahydrochloride) substrate kit (manufactured by Dako) to HRP bound to the secondary antibody.
- FIG. 1 is a diagram showing the results of immunostaining of CYP11B2.
- FIG. 1A is an overall view of a section
- FIG. 1B is a 20-fold enlarged view of a non-ischemic site (ROIa in FIG. 1A)
- FIG. It is a 20 times enlarged view of a perfusion site (ROIb in FIG. 1 (a))
- FIG. 1 (d) is a 20 times enlarged view of an ischemia reperfusion site (ROIc in FIG. 1 (a)).
- FIG. 1 it was confirmed that CYP11B2 was expressed at the ischemia reperfusion site. Further, it was confirmed that CYP11B2 is not expressed or is not expressed at a non-ischemic site.
- Example 2 Ex vivo autoradiography using an ischemic heart disease model rat An ischemic heart disease model rat was prepared in the same manner as in Example 1, and the compound [ 18 F] was used within 1 to 3 weeks after the operation. 1 was administered (approximately 50 MBq / animal). Twenty minutes after the administration, the rats were sacrificed under anesthesia, the heart was taken out, and a 20 ⁇ m-thick frozen section was prepared from the base of the heart toward the apex. The prepared section was exposed to an imaging plate (BAS-SR2040, manufactured by Fujifilm) for 2 hours, and an autoradiogram was obtained with a fluoro image analyzer (FLA-7000, manufactured by GE Healthcare). Further, HE section staining, Masson trichrome staining, and immunostaining of CYP11B2 were performed in the same manner as in Example 1 using the section adjacent to the base portion side section.
- BAS-SR2040 manufactured by Fujifilm
- FIG. 2 shows the autoradiogram results of an individual administered with Compound [ 18 F] 1.
- FIG. 2A autoradiograms of the respective sections are shown side by side from the base to the apex.
- FIG. 2B is an enlarged view after the autogram surrounded by a broken line in FIG. 2A is rotated by 90 degrees.
- FIG. 3 shows the staining result of the section adjacent to the section shown in FIG.
- FIG. 3A shows the result of HE staining
- FIG. 3B shows the result of Masson trichrome staining
- FIG. 3C shows the result of immunostaining of CYP11B2.
- FIG. 2 local accumulation of compound [ 18 F] 1 was confirmed.
- FIG. 3 inflammatory reaction, fibrosis, and expression of CYP11B2 were confirmed at the position corresponding to the accumulation portion of compound [ 18 F] 1.
- Example 3 In vitro autoradiography using an ischemic heart disease model rat After preparing an ischemic heart disease model rat in the same manner as in Example 1 and slaughtering under isoflurane anesthesia for 1 to 3 weeks after the operation. The heart was removed and 5 ⁇ m sections were prepared and stored at ⁇ 80 ° C. until use. The section is returned from -80 ° C. to room temperature, dried for 30 minutes or more, then immersed in phosphate buffered saline for 30 minutes, and then immersed in phosphate buffered saline containing 1 w / v% bovine serum albumin for 30 minutes. To make it hydrophilic.
- Each prepared and hydrophilized section was immersed for 30 minutes at room temperature. Thereafter, the sections were washed by immersing each of the solutions of 1 w / v% bovine serum albumin-containing phosphate buffered saline, phosphate buffered saline, and phosphate buffered saline for 5 minutes.
- Compound [ 18 F] 1 was exposed for about 3 hours and Compound [ 123 I] 2 was exposed for about 16 hours on an imaging plate (BAS-SR2040, manufactured by FUJIFILM Corporation).
- -An autoradiogram was acquired using an image analyzer (FLA-7000, manufactured by GE Healthcare). Further, an autoradiogram is obtained by similarly immersing the sections in a solution containing 5 ⁇ mol / L of Compound [ 18 F] 1 and Compound 1 or a solution containing 5 ⁇ mol / L of Compound [ 123 I] 2 and Compound 2. did.
- the same experiment was performed using the heart extracted from the normal rat.
- FIG. 4 (a) and 4 (e) are sections of normal rats
- FIGS. 4 (b) to (d) and (f) to (h) are sections of ischemic heart disease model rats.
- FIGS. 4 (a) to (d) are immersed in a liquid containing the compound [ 18 F] 1
- FIGS. 4 (e) to (h) are the compounds [ 18 F] 1 and 1 (5 ⁇ mol). / L).
- FIG. 4 accumulation of compound [ 18 F] 1 in the lesion area was confirmed.
- accumulation was inhibited by adding an excessive amount of unlabeled compound, suggesting that the binding was specific.
- FIG. 5 (a) and 5 (c) are sections of normal rats
- FIGS. 5 (b) and 5 (d) are sections of ischemic heart disease model rats.
- FIGS. 5A and 5B are immersed in a liquid containing the compound [ 123 I] 2
- FIGS. 5C and 5D show the compounds [ 123 I] 2 and 2 (5 ⁇ mol). / L).
- accumulation of compound [ 123 I] 2 in the lesion area was confirmed.
- accumulation was inhibited by adding an excessive amount of unlabeled compound, suggesting that the binding was specific.
- FIG. 6A shows the result of autoradiography.
- FIG. 6 (b) shows the result of Masson trichrome staining, and
- FIG. 6 (c) shows the result of immunostaining of CYP11B2.
- the accumulation of compound [ 123 I] 2 was in good agreement with the fibrotic region.
- the expression of CYP11B2 at the ischemia reperfusion site was confirmed.
- FIG. 7A is an example of an autoradiogram of a section immersed in the compound [ 18 F] 1.
- FIG. 7C is an example of an autoradiogram of a section immersed in the compound [ 123 I] 2.
- the ROI at the ischemia / reperfusion site is surrounded by the solid line, and the ROI at the non-ischemic site is surrounded by the broken line.
- FIG. 7B is a bar graph showing the signal intensity ratio of the compound [ 18 F] 1 at the ischemia / reperfusion site / non-ischemic site in each rat.
- FIG. 7D shows a bar graph of the signal intensity ratio of the compound [ 123 I] 2 at the ischemia / reperfusion site / non-ischemic site in each rat.
- an increase in accumulation of Compound [ 18 F] 1 and Compound [ 123 I] 2 at the ischemia-reperfusion site compared to the non-ischemic site was observed.
- the compound [ 123 I] 2 showed higher accumulation than the compound [ 18 F] 1.
- Example 4 Examination of influence on compound accumulation by time course after preparation of ischemic heart disease model rats As in Example 1, ischemic heart disease model rats were prepared, and one day after surgery (3 animals), 3 On day (4 animals) and 1 week (4 animals), the mice were sacrificed under anesthesia with isoflurane, and then the heart was removed to prepare 5 ⁇ m sections and stored at ⁇ 80 ° C. until use. The section is returned from -80 ° C. to room temperature, dried for 30 minutes or more, then immersed in phosphate buffered saline for 30 minutes, and then immersed in phosphate buffered saline containing 1 w / v% bovine serum albumin for 30 minutes. To make it hydrophilic.
- 1 w / v% bovine serum albumin-containing phosphate buffered saline containing compound [ 123 I] 2 (radioactive concentration: about 10 kBq / mL) was prepared, and the hydrophilized section was immersed for 30 minutes at room temperature. Thereafter, the sections were washed by immersing each of the solutions of 1 w / v% bovine serum albumin-containing phosphate buffered saline, phosphate buffered saline, and phosphate buffered saline for 5 minutes.
- FIG. 8 (a) shows the ischemia-reperfusion site of compound [ 123I ] 2 by autoradiography using the hearts of normal rats and ischemic heart disease model rats 1 day, 3 days and 1 week after the preparation.
- the signal intensity / signal intensity ratio at the non-ischemic site is shown by a bar graph.
- FIG. 8 (b) shows the results of Masson trichrome staining using a section adjacent to the section used in FIG. 8 (a).
- the accumulation of the compound [ 123 I] 2 increased with time after the operation.
- FIG. 8 (b) it was confirmed that fibrosis was promoted over time after the operation.
- Example 5 SPECT imaging experiment using an ischemic heart disease model rat
- An ischemic heart disease model rat was prepared in the same manner as in Example 1, and the compound [ 123 I] 2 was administered 1 week after the operation (about 100 MBq). From 150 minutes after administration, static imaging was performed for about 8 minutes using an animal SPECT device (FX3000, manufactured by TriFoil). Acquisition was performed with an energy window of 143-175 keV, and the collected data was reconstructed and imaged by the OSEM (Ordered Subset Expectation Maximization) method. Computed Tomography imaging was performed to determine the position of the heart. The same experiment was conducted using normal rats.
- FIG. 9A to 9C show the results of SPECT imaging with compound [ 123 I] 2 using normal rats.
- the H arrow indicates the heart
- the L arrow indicates the liver.
- 9 (d) to (f) show the results of SPECT imaging with compound [ 123 I] 2 using ischemic heart disease model rats.
- 9 (d) to 9 (f) the arrow i indicates the ischemia / reperfusion site.
- 9 (a) and 9 (d) are short-axis cross-sectional images
- FIGS. 9 (b) and 9 (e) are horizontal long-axis cross-sectional images
- FIGS. 9 (c) and 9 (f) are vertical long-axis cross-sectional images. It is.
- Each of the SPECT images in FIG. 9 was displayed so as to overlap with the computed tomography image. As shown in FIG. 9, accumulation of compound [ 123 I] 2 that was not observed in the normal rat heart was confirmed in the ischemic heart disease model rat heart.
- Example 6 Evaluation of CYP11B2 expression in heart muscle model rat heart
- Porcine heart cardiac myosin (Sigma-Aldrich) was diluted to 5 mg / mL with a phosphate buffer (solution A).
- 100 mg of Mycobacterium tuberculosis H37Ra (Difco) was added to 10 mL of adjuvant complete Freund (Sigma-Aldrich) and mixed (solution B).
- Solution A and solution B were mixed at a ratio of 1: 1 until the solution was uniform (solution C).
- Solution C was administered to the left and right hind leg footpads of Lewis rats (male, 7 weeks old, Charles River, Japan) under isoflurane anesthesia.
- the anti-CYP11B2 antibody was prepared according to the method described in Ogishima T et al, Endocrinology, 1992, vol. 130, pp.2971-7, and the secondary antibody was HRP Labeled Polymer Anti-Rabbit (manufactured by Dako). Was used.
- the CYP11B2 expression site was detected by applying DAB + (3,3′-diaminobenzidine tetrahydrochloride) substrate kit (manufactured by Dako) to HRP bound to the secondary antibody.
- DAB + (3,3′-diaminobenzidine tetrahydrochloride) substrate kit (manufactured by Dako)
- Dako Dako
- a similar experiment was performed using a heart extracted from a rat (normal rat) that normally raised Lewis rats.
- FIG. 10 is a diagram showing the results of immunostaining of CYP11B2.
- FIG. 10A is an overall view of a cardiac tissue section of a myocarditis model
- FIG. 10B is a 40 times enlarged view of the lesioned part in FIG.
- Fig. 10 (c) is an overall view of a heart tissue section of a normal rat
- Fig. 10 (d) is a 40 times enlarged view of the normal part in Fig. 10 (c).
- FIG. 10 it was confirmed that CYP11B2 was expressed in the heart of a myocarditis model rat. In addition, it was confirmed that CYP11B2 is not expressed or is not expressed in the heart of normal rats.
- Example 7 In vitro autoradiography using a myocarditis model rat A myocarditis model rat was prepared in the same manner as in Example 6, and the heart was excised to prepare a 5 ⁇ m section, which was kept at ⁇ 80 ° C. until use. saved. The section is returned from -80 ° C. to room temperature, dried for 30 minutes or more, then immersed in phosphate buffered saline for 30 minutes, and then immersed in phosphate buffered saline containing 1 w / v% bovine serum albumin for 30 minutes. To make it hydrophilic.
- 1 w / v% bovine serum albumin-containing phosphate buffered saline containing compound [ 123 I] 3 (radioactive concentration: about 10 kBq / mL) was prepared, and the hydrophilized sections were immersed for 30 minutes at room temperature. Thereafter, the sections were washed by immersing each of the solutions of 1 w / v% bovine serum albumin-containing phosphate buffered saline, phosphate buffered saline, and phosphate buffered saline for 5 minutes.
- the compound [ 123 I] 3 was exposed for about 16 hours on an imaging plate (BAS-SR2040, manufactured by FUJIFILM Corporation), and Fluoro Image Analyzer (FLA-7000, GE Healthcare). Autoradiogram was obtained using a Moreover, the same experiment was performed using the heart extracted from the normal rat. Using a section adjacent to the section used for autoradiography, Masson trichrome staining and CYP11B2 immunostaining similar to Example 6 were performed.
- FIG. 11 shows the result of in vitro autoradiography of the compound [ 123 I] 3.
- FIG. 11 (a) shows the results of autoradiography of heart tissue sections of normal rats
- FIG. 11 (b) shows the results of autoradiography of heart tissue sections of myocarditis model rats.
- FIG. 11 (c) shows the results of Masson trichrome staining of heart tissue sections of normal rats
- FIG. 11 (d) shows the results of Masson trichrome staining of heart tissue sections of myocarditis model rats.
- FIG. 11 (e) shows the result of CYP11B2 immunostaining of normal rat heart tissue section
- FIG. 11 (f) shows the result of CYP11B2 immunostaining of heart tissue section of myocarditis model rat.
- increased accumulation of compound [ 123 I] 3 was confirmed in heart tissue sections of myocarditis model rats compared to heart tissue sections of normal rats.
- the accumulation of compound [ 123 I] 3 closely coincided with the fibrosis region, and the expression of CYP11B2 in the fibrosis region was confirmed.
- Example 8 Evaluation of CYP11B2 expression in the heart of a hypertensive heart disease model rat DIS / Eis (Dahl-Iwai S) rats (male, SLC Japan) fed 8% salt-added diet (oriental yeast) from 5 weeks of age After raising to 11 weeks of age, the rats were sacrificed under anesthesia, the heart was taken out, and 5 ⁇ m thick sections were prepared. Using the prepared sections, immunostaining was performed to confirm the expression and distribution of CPY11B2.
- the anti-CYP11B2 antibody was prepared according to the method described in Ogishima T et al, Endocrinology, 1992, vol.
- FIG. 12 is a diagram showing the results of immunostaining of CYP11B2.
- FIG. 12 (a) is an overall view of a heart tissue section of a hypertensive heart disease model rat
- FIG. 12 (b) is a 40 times enlarged view of the lesioned part in FIG. 12 (a).
- FIG. 12 (c) is an overall view of a heart tissue section of a normal rat
- FIG. 12 (d) is a 40 times enlarged view of the normal part in FIG. 12 (c).
- FIG. 12 it was confirmed that CYP11B2 is expressed in the hypertensive heart disease model rat heart. In normal rats, it was confirmed that CYP11B2 was not expressed or the expression was low.
- Example 9 In vitro autoradiography using hypertensive heart disease model rats Hypertensive heart disease model rats were prepared in the same manner as in Example 8. The heart was removed, 5 ⁇ m sections were prepared, and stored at ⁇ 80 ° C. until use. The section is returned from -80 ° C. to room temperature, dried for 30 minutes or more, then immersed in phosphate buffered saline for 30 minutes, and then immersed in phosphate buffered saline containing 1 w / v% bovine serum albumin for 30 minutes. To make it hydrophilic.
- 1 w / v% bovine serum albumin-containing phosphate buffered saline containing compound [ 123 I] 3 (radioactive concentration: about 10 kBq / mL) was prepared, and the hydrophilized sections were immersed for 30 minutes at room temperature. Thereafter, the sections were washed by immersing each of the solutions of 1 w / v% bovine serum albumin-containing phosphate buffered saline, phosphate buffered saline, and phosphate buffered saline for 5 minutes.
- Example 8 After thoroughly washing the sections after washing, the compound [ 123 I] 3 was exposed for about 16 hours on an imaging plate (BAS-SR2040, manufactured by FUJIFILM Corporation), and Fluoro Image Analyzer (FLA-7000, GE Healthcare). Autoradiogram was obtained using a Moreover, the same experiment was performed using the heart extracted from the normal rat. Using a section adjacent to the section used for autoradiography, Masson trichrome staining and CYP11B2 immunostaining similar to Example 8 were performed.
- FIG. 13 (a) shows the results of autoradiography of heart tissue sections of normal rats
- FIG. 13 (b) shows the results of autoradiography of heart tissue sections of hypertensive heart disease model rats.
- FIG. 13 (c) shows the results of Masson trichrome staining of heart tissue sections of normal rats
- FIG. 13 (d) shows the results of Masson trichrome staining of heart tissue sections of hypertensive heart disease model rats.
- FIG. 13 (e) shows the results of CYP11B2 immunostaining of normal rat heart tissue sections
- FIG. 13 (e) shows the results of CYP11B2 immunostaining of normal rat heart tissue sections
- FIG. 13 (f) shows the results of CYP11B2 immunostaining of heart tissue sections of hypertensive heart disease model rats.
- increased accumulation of compound [ 123 I] 3 was confirmed compared to the heart tissue section of a normal rat.
- the accumulation of compound [ 123 I] 3 closely coincided with the fibrosis region, and the expression of CYP11B2 in the fibrosis region was confirmed.
- Example 10 In vitro autoradiography using ischemic heart disease model rats
- ischemic heart disease model rats were prepared and sacrificed under isoflurane anesthesia for 1 week after the operation. 5 ⁇ m sections were prepared by extraction and stored at ⁇ 80 ° C. until use. The section is returned from -80 ° C. to room temperature, dried for 30 minutes or more, then immersed in phosphate buffered saline for 30 minutes, and then immersed in phosphate buffered saline containing 1 w / v% bovine serum albumin for 30 minutes. To make it hydrophilic.
- 1 w / v% bovine serum albumin-containing phosphate buffered saline containing compound [ 123 I] 3 (radioactive concentration: about 10 kBq / mL) was prepared, and the hydrophilized sections were immersed for 30 minutes at room temperature. Thereafter, the sections were washed by immersing each of the solutions of 1 w / v% bovine serum albumin-containing phosphate buffered saline, phosphate buffered saline, and phosphate buffered saline for 5 minutes.
- FIG. 14 (a) shows a slice of a normal rat immersed in a solution containing compound [ 123I ] 3.
- FIG.14 (b) shows a slice of an ischemic heart disease model rat obtained with compound [ 123I ] 3. It is immersed in the liquid containing. As shown in FIG. 14, an increase in the accumulation of compound [ 123 I] 3 in the lesion area compared to normal rats was confirmed.
- a radiolabeled compound capable of binding to aldosterone synthase can perform nuclear medicine diagnosis of myocardial remodeling process such as fibrosis progression in heart disease patients.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
本発明において「虚血性心疾患」とは、心筋虚血により生じる心疾患であれば限定されず、例えば、冠動脈性心疾患狭心症、心筋梗塞、急性冠症候群、虚血性心不全などが挙げられる。
また、本発明において「非虚血性心疾患」とは、心筋炎、高血圧性心疾患、拡張型心筋症、肥大型心筋症、非虚血性心不全などが挙げられる。
(a)R2にハロゲン原子として放射性ハロゲン原子を用いる。
(b)R5を-(CH2)nX4で表される基とし、かつ、X4のハロゲン原子として放射性ハロゲン原子を用いる。
(c)R5をp-ハロベンジル基とし、かつ、ベンジル基の4位の導入されたハロゲン原子として放射性ハロゲン原子を用いる。
(d)X2のハロゲン原子として放射性ハロゲン原子を用いる。
下記実施例において、実験に供する化合物の名称を以下のように定義した。
化合物1:6-クロロ-5-フルオロ-1-(2-フルオロエチル)-2-[5-(イミダゾール-1-イルメチル)ピリジン-3-イル]ベンゾイミダゾール
化合物[18F]1:6-クロロ-5-フルオロ-1-(2-[18F]フルオロエチル)-2-[5-(イミダゾール-1-イルメチル)ピリジン-3-イル]ベンゾイミダゾール(一般式(2)で表わされる化合物において、R12は水素原子を示し、X11はフッ素原子を示し、X12は塩素原子を示し、X14はフッ素-18を示し、nは整数2を示す化合物)
化合物2:1-(2-フルオロエチル)-2-[5-{(イミダゾール-1-イル)メチル}ピリジン-3-イル]-6-ヨードベンゾイミダゾール
化合物[123I]2:1-(2-フルオロエチル)-2-[5-{(イミダゾール-1-イル)メチル}ピリジン-3-イル]-6-[123I]ヨードベンゾイミダゾール(一般式(2)で表わされる化合物において、R12は水素原子を示し、X11は水素原子を示し、X12はヨウ素-123を示し、X14はフッ素原子を示し、nは整数2を示す化合物)
化合物3:2-[5-{(1H-イミダゾール-1-イル)メチル}ピリジン-3-イル]-6-ヨード-1-メチル-1H-ベンゾ[d]イミダゾール
化合物[123I]3:2-[5-{(1H-イミダゾール-1-イル)メチル}ピリジン-3-イル]-6-[123I]ヨード-1-メチル-1H-ベンゾ[d]イミダゾール(一般式(2)で表わされる化合物において、R12は水素原子を示し、X11は水素原子を示し、X12はヨウ素-123を示し、X14は水素原子を示し、nは整数1を示す化合物)
化合物[18F]1については、国際公開2015/199205パンフレットの化合物[18F]100の合成法に従って合成し、同開示のTLC条件下で放射化学的純度95%以上のものを使用した。
化合物2については、国際公開2015/199205パンフレットの化合物604の合成法に従って合成した。
化合物[123I]2については、国際公開2015/199205パンフレットの化合物[123I]604の合成法に従って合成し、同開示のTLC条件下で放射化学的純度95%以上のものを使用した。
化合物3については、国際公開2015/199205パンフレットの化合物607の合成法に従って合成した。
化合物[123I]3については、国際公開2015/199205パンフレットの化合物[123I]607の合成法に従って合成し、同開示のTLC条件下で放射化学的純度95%以上のものを使用した。
Wistarラット(雄)をイソフルラン麻酔下で開胸し、左冠動脈を30分間結紮した後、再灌流し、閉胸し、虚血性心疾患モデルラットを作製した。手術後約1週間に、ラットを麻酔下で屠殺、心臓を取出し、心基部側から5μm厚の切片を作製した。作製した切片を用い、免疫染色を実施し、CPY11B2の発現・分布を確認した。抗CYP11B2抗体は、Ogishima T et al, Endocrinology, 1992, vol. 130, pp.2971-7記載の方法に従って作製されたものを用い、二次抗体にはHRP Labelled Polymer Anti-Rabbit(Dako社製)を用いた。二次抗体に結合するHRPに対してDAB+(3、3’-ジアミノベンジジンテトラヒドロクロライド)・基質キット(Dako社製)を適用することで、CYP11B2発現部位を検出した。
実施例1と同様に虚血性心疾患モデルラットを作製し、手術後1週から3週の間に、化合物[18F]1を投与した(約50MBq/匹)。投与後20分に麻酔下でラットを屠殺し、心臓を取出し、心基部から心尖部に向かって20μm厚の凍結切片を作製した。作製した切片をイメージングプレート(BAS-SR2040、富士フイルム社製)に2時間曝露し、フルオロ・イメージアナライザー(FLA-7000、GEヘルスケア社製)でオートラジオグラムを取得した。
また、心基部側切片の隣接切片を用いて、HE染色、マッソン・トリクローム染色、実施例1と同様、CYP11B2の免疫染色をそれぞれ実施した。
図2で図示するように、化合物[18F]1の局所的な集積が確認された。また、図3の染色結果から、化合物[18F]1の集積部分に対応する位置に、炎症反応、線維化、CYP11B2の発現が確認された。
実施例1と同様に虚血性心疾患モデルラットを作製し、手術後1週から3週の間にイソフルラン麻酔下で屠殺後、心臓を摘出して5μmの切片を作製し、使用時まで-80℃下で保存した。切片を-80℃から室温へ戻し、30分間以上乾燥させた後、リン酸緩衝生理食塩水に30分間浸漬し、次に1w/v%ウシ血清アルブミン含有リン酸緩衝生理食塩水に30分間浸漬することで親水化を行った。化合物[18F]1(放射能濃度:約40kBq/mL)又は化合物[123I]2(放射能濃度:約10kBq/mL)を含む1w/v%ウシ血清アルブミン含有リン酸緩衝生理食塩水をそれぞれ調製し、親水化した切片を室温下で30分間浸漬した。その後、1w/v%ウシ血清アルブミン含有リン酸緩衝生理食塩水、リン酸緩衝生理食塩水、リン酸緩衝生理食塩水の各溶液について5分間ずつ浸漬し、切片の洗浄を行った。洗浄後の切片を十分に乾燥した後、イメージングプレート(BAS-SR2040、富士フイルム社製)上で化合物[18F]1は約3時間、化合物[123I]2は約16時間露光させ、フルオロ・イメージアナライザー(FLA-7000、GEヘルスケア社製)を用いてオートラジオグラムを取得した。
また、化合物[18F]1及び化合物1を5μmol/Lを含む液、又は、化合物[123I]2及び化合物2を5μmol/Lを含む液に同様に切片を浸漬させ、オートラジオグラムを取得した。
また、正常ラットから摘出した心臓を用いて同様の実験を行った。
実施例1と同様に虚血性心疾患モデルラットを作製し、手術後1日(3匹)、3日(4匹)及び1週(4匹)にイソフルラン麻酔下で屠殺後、心臓を摘出して5μmの切片を作製し、使用時まで-80℃下で保存した。切片を-80℃から室温へ戻し、30分間以上乾燥させた後、リン酸緩衝生理食塩水に30分間浸漬し、次に1w/v%ウシ血清アルブミン含有リン酸緩衝生理食塩水に30分間浸漬することで親水化を行った。化合物[123I]2(放射能濃度:約10kBq/mL)を含む1w/v%ウシ血清アルブミン含有リン酸緩衝生理食塩水を調製し、親水化した切片を室温下で30分間浸漬した。その後、1w/v%ウシ血清アルブミン含有リン酸緩衝生理食塩水、リン酸緩衝生理食塩水、リン酸緩衝生理食塩水の各溶液について5分間ずつ浸漬し、切片の洗浄を行った。洗浄後の切片を十分に乾燥した後、イメージングプレート(BAS-SR2040、富士フイルム社製)上で約16時間露光させ、フルオロ・イメージアナライザー(FLA-7000、GEヘルスケア社製)を用いてオートラジオグラムを取得した。
また、正常ラット(2匹)から摘出した心臓を用いて同様の実験を行った。
実施例1と同様に虚血性心疾患モデルラットを作製し、手術後1週間に化合物[123I]2を投与し(約100MBq/匹)、投与後150分より、動物用SPECT装置(FX3000、TriFoil社製)を用い、約8分間のstatic撮像を実施した。収集は、143-175keVのエネルギーウィンドウで実施し、収集したデータはOSEM(Ordered Subset Expectation Maximization)法により再構成して画像化した。心臓の位置を特定するためにComputed Tomography撮像を実施した。また、正常ラットを用いて同様の実験を行った。
Porcine heart cardiac myosin(Sigma-Aldrich)を5mg/mLになるようリン酸緩衝液を用いて希釈した(溶液A)。アジュバントコンプリートフロイント(Sigma-Aldrich)10mLに結核菌H37Ra(Difco)100mgを添加し、混和した(溶液B)。溶液A及び溶液Bを1:1の割合で溶液が均一になるまで混合した(溶液C)。溶液CをLewisラット(雄、7週齢、日本チャールズリバー)の左右の後肢足蹠に50μLずつイソフルラン麻酔下で投与した。免疫化後21日まで飼育後、ラットを麻酔下で屠殺、心臓を取出し、5μm厚の切片を作製した。作製した切片を用い、免疫染色を実施し、CPY11B2の発現・分布を確認した。抗CYP11B2抗体は、Ogishima T et al, Endocrinology, 1992, vol. 130, pp.2971-7記載の方法に従って作製されたものを用い、二次抗体にはHRP Labelled Polymer Anti-Rabbit(Dako社製)を用いた。二次抗体に結合するHRPに対してDAB+(3、3’-ジアミノベンジジンテトラヒドロクロライド)・基質キット(Dako社製)を適用することで、CYP11B2発現部位を検出した。また、Lewisラットを通常飼育したラット(正常ラット)から摘出した心臓を用いて同様の実験を行った。
実施例6と同様に心筋炎モデルラットを作製し、心臓を摘出して5μmの切片を作製し、使用時まで-80℃下で保存した。切片を-80℃から室温へ戻し、30分間以上乾燥させた後、リン酸緩衝生理食塩水に30分間浸漬し、次に1w/v%ウシ血清アルブミン含有リン酸緩衝生理食塩水に30分間浸漬することで親水化を行った。化合物[123I]3(放射能濃度:約10kBq/mL)を含む1w/v%ウシ血清アルブミン含有リン酸緩衝生理食塩水をそれぞれ調製し、親水化した切片を室温下で30分間浸漬した。その後、1w/v%ウシ血清アルブミン含有リン酸緩衝生理食塩水、リン酸緩衝生理食塩水、リン酸緩衝生理食塩水の各溶液について5分間ずつ浸漬し、切片の洗浄を行った。洗浄後の切片を十分に乾燥した後、イメージングプレート(BAS-SR2040、富士フイルム社製)上で化合物[123I]3を約16時間露光させ、フルオロ・イメージアナライザー(FLA-7000、GEヘルスケア社製)を用いてオートラジオグラムを取得した。また、正常ラットから摘出した心臓を用いて同様の実験を行った。オートラジオグラフィーに使用した切片の隣接切片を用いて、マッソン・トリクローム染色、実施例6と同様のCYP11B2の免疫染色をそれぞれ実施した。
DIS/Eis(Dahl-Iwai S)ラット(雄、日本エスエルシー)に5週齢から8%食塩添加飼料(オリエンタル酵母)を給餌し、11週齢まで飼育後、ラットを麻酔下で屠殺、心臓を取出し、5μm厚の切片を作製した。作製した切片を用い、免疫染色を実施し、CPY11B2の発現・分布を確認した。抗CYP11B2抗体は、Ogishima T et al, Endocrinology, 1992, vol. 130, pp.2971-7記載の方法に従って作製されたものを用い、二次抗体にはHRP Labelled Polymer Anti-Rabbit(Dako社製)を用いた。二次抗体に結合するHRPに対してDAB+(3、3’-ジアミノベンジジンテトラヒドロクロライド)・基質キット(Dako社製)を適用することで、CYP11B2発現部位を検出した。また、DIS/Eisラットを食塩非添加の飼料で飼育したラット(正常ラット)から摘出した心臓を用いて同様の実験を行った。
実施例8と同様に高血圧性心疾患モデルラットを作製し、心臓を摘出して5μmの切片を作製し、使用時まで-80℃下で保存した。切片を-80℃から室温へ戻し、30分間以上乾燥させた後、リン酸緩衝生理食塩水に30分間浸漬し、次に1w/v%ウシ血清アルブミン含有リン酸緩衝生理食塩水に30分間浸漬することで親水化を行った。化合物[123I]3(放射能濃度:約10kBq/mL)を含む1w/v%ウシ血清アルブミン含有リン酸緩衝生理食塩水をそれぞれ調製し、親水化した切片を室温下で30分間浸漬した。その後、1w/v%ウシ血清アルブミン含有リン酸緩衝生理食塩水、リン酸緩衝生理食塩水、リン酸緩衝生理食塩水の各溶液について5分間ずつ浸漬し、切片の洗浄を行った。洗浄後の切片を十分に乾燥した後、イメージングプレート(BAS-SR2040、富士フイルム社製)上で化合物[123I]3を約16時間露光させ、フルオロ・イメージアナライザー(FLA-7000、GEヘルスケア社製)を用いてオートラジオグラムを取得した。また、正常ラットから摘出した心臓を用いて同様の実験を行った。オートラジオグラフィーに使用した切片の隣接切片を用いて、マッソン・トリクローム染色、実施例8と同様のCYP11B2の免疫染色をそれぞれ実施した。
実施例1と同様に虚血性心疾患モデルラットを作製し、手術後1週の間にイソフルラン麻酔下で屠殺後、心臓を摘出して5μmの切片を作製し、使用時まで-80℃下で保存した。切片を-80℃から室温へ戻し、30分間以上乾燥させた後、リン酸緩衝生理食塩水に30分間浸漬し、次に1w/v%ウシ血清アルブミン含有リン酸緩衝生理食塩水に30分間浸漬することで親水化を行った。化合物[123I]3(放射能濃度:約10kBq/mL)を含む1w/v%ウシ血清アルブミン含有リン酸緩衝生理食塩水をそれぞれ調製し、親水化した切片を室温下で30分間浸漬した。その後、1w/v%ウシ血清アルブミン含有リン酸緩衝生理食塩水、リン酸緩衝生理食塩水、リン酸緩衝生理食塩水の各溶液について5分間ずつ浸漬し、切片の洗浄を行った。洗浄後の切片を十分に乾燥した後、イメージングプレート(BAS-SR2040、富士フイルム社製)上で約16時間露光させ、フルオロ・イメージアナライザー(FLA-7000、GEヘルスケア社製)を用いてオートラジオグラムを取得した。また、正常ラットから摘出した心臓を用いて同様の実験を行った。
Claims (12)
- アルドステロン合成酵素に結合能を有する放射性標識化合物又はその塩を有効成分として含有する、心疾患の非侵襲的画像診断剤。
- 前記放射性標識化合物は、炭素-11、フッ素-18、塩素-34m、臭素-76、ヨウ素-123又はヨウ素-124で標識されたものである、請求項1に記載の非侵襲的画像診断剤。
- 前記放射性標識化合物が下記一般式(1)で表わされる、請求項1に記載の非侵襲的画像診断剤。
〔上記一般式(1)中、R1は、水素原子又はCO2Raを示し、R2は、水素原子、ハロゲン原子又はCO2Raを示し、R3は、水素原子又は炭素数1~10のヒドロキシアルキル基を示し、R4は、水素原子、ヒドロキシ基又は炭素数1~10のアルコキシ基を示し、R5は、水素原子がハロゲン原子で置換されていてもよい、炭素数1~5の鎖状アルキル基、水素原子がハロゲン原子で置換されていてもよい、炭素数3~5の環状アルキル基、炭素数1~5のヒドロキシアルキル基、又は、o-、p-もしくはm-ハロベンジル基を示し、Aは、CH又は窒素原子を示し、X1及びX3は、各々独立して、水素原子又はハロゲン原子を示し、X2は、水素原子、ハロゲン原子又はニトリル基を示すが、X1、X2及びX3の少なくとも1つはハロゲン原子であり、Raは、各々独立して、炭素数1~10のアルキル基を示し、R2、R5、又は、X2のいずれか1つが放射性ハロゲン原子を含む。〕 - 前記一般式(2)中、R12は、水素原子であり、X12、又は、X14が放射性ハロゲン原子である、請求項4に記載の非侵襲的画像診断剤。
- 前記一般式(2)中、nは、1~3の整数を示す、請求項4又は5に記載の非侵襲的画像診断剤。
- 前記放射性ハロゲン原子は、フッ素-18、塩素-34m、臭素-76、ヨウ素-123又はヨウ素-124である、請求項3乃至6いずれか一項に記載の非侵襲的画像診断剤。
- ポジトロン放出断層撮影又はシングルフォトン断層撮影に用いられるための請求項1乃至7いずれか一項に記載の非侵襲的画像診断剤。
- 前記心疾患が虚血性心疾患である、請求項1乃至8いずれか一項に記載の非侵襲的画像診断剤。
- 前記虚血性心疾患は、冠動脈性心疾患狭心症、心筋梗塞、急性冠症候群又は虚血性心不全である、請求項9に記載の非侵襲的画像診断剤。
- 前記心疾患が非虚血性心疾患である、請求項1乃至8いずれか一項に記載の非侵襲的画像診断剤。
- 前記非虚血性心疾患が、心筋炎、高血圧性心疾患、拡張型心筋症、肥大型心筋症又は非虚血性心不全である、請求項11に記載の非侵襲的画像診断剤。
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018521787A JPWO2017213247A1 (ja) | 2016-06-10 | 2017-06-09 | 心疾患の非侵襲的画像診断剤 |
CN201780035800.9A CN109310787A (zh) | 2016-06-10 | 2017-06-09 | 心脏病的非侵入性影像诊断剂 |
EP17810420.4A EP3470091A4 (en) | 2016-06-10 | 2017-06-09 | NON-INVASIVE DIAGNOSTIC IMAGING AGENT FOR CARDIAC DISEASE |
KR1020187036667A KR20190016971A (ko) | 2016-06-10 | 2017-06-09 | 심질환의 비침습적 화상 진단제 |
CA3026617A CA3026617A1 (en) | 2016-06-10 | 2017-06-09 | Non-invasive diagnostic imaging agent for heart disease |
SG11201810847RA SG11201810847RA (en) | 2016-06-10 | 2017-06-09 | Non-invasive diagnostic imaging agent for heart disease |
US16/308,014 US20190255199A1 (en) | 2016-06-10 | 2017-06-09 | Non-invasive diagnostic imaging agent for heart disease |
AU2017278446A AU2017278446A1 (en) | 2016-06-10 | 2017-06-09 | Non-invasive diagnostic imaging agent for heart disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016115806 | 2016-06-10 | ||
JP2016-115806 | 2016-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017213247A1 true WO2017213247A1 (ja) | 2017-12-14 |
Family
ID=60577959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2017/021442 WO2017213247A1 (ja) | 2016-06-10 | 2017-06-09 | 心疾患の非侵襲的画像診断剤 |
Country Status (9)
Country | Link |
---|---|
US (1) | US20190255199A1 (ja) |
EP (1) | EP3470091A4 (ja) |
JP (1) | JPWO2017213247A1 (ja) |
KR (1) | KR20190016971A (ja) |
CN (1) | CN109310787A (ja) |
AU (1) | AU2017278446A1 (ja) |
CA (1) | CA3026617A1 (ja) |
SG (1) | SG11201810847RA (ja) |
WO (1) | WO2017213247A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019131458A1 (ja) * | 2017-12-28 | 2019-07-04 | 日本メジフィジックス株式会社 | 2-[5-(イミダゾール-1-イルメチル)ピリジン-3-イル]ベンズイミダゾール誘導体化合物、及び、これを含む医薬 |
WO2019216223A1 (ja) * | 2018-05-08 | 2019-11-14 | 日本メジフィジックス株式会社 | 心疾患の非侵襲的画像診断剤 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013512271A (ja) * | 2009-11-30 | 2013-04-11 | ノバルティス アーゲー | アルドステロン合成酵素阻害剤としてのイミダゾール誘導体 |
JP2014526539A (ja) * | 2011-09-23 | 2014-10-06 | エフ.ホフマン−ラ ロシュ アーゲー | 新規な二環式ジヒドロキノリン−2−オン誘導体 |
WO2015199205A1 (ja) * | 2014-06-26 | 2015-12-30 | 日本メジフィジックス株式会社 | 2-(3-ピリジニル)-1h-ベンゾイミダゾール誘導体化合物、及び、これを含む医薬 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602008003015D1 (de) * | 2007-03-29 | 2010-11-25 | Novartis Ag | Heterocyclische spiroverbindungen |
JP5196561B2 (ja) * | 2007-11-07 | 2013-05-15 | 独立行政法人放射線医学総合研究所 | 核医学診断用医薬 |
DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
EP2394668A1 (en) | 2010-06-01 | 2011-12-14 | Julius-Maximilians-Universität Würzburg | PET radiopharmaceuticals for differential diagnosis between bilateral and unilateral conditions of primary hyperaldosteronism |
JP6048958B2 (ja) | 2012-12-27 | 2016-12-21 | 日本メジフィジックス株式会社 | 副腎疾患の画像診断剤 |
JP2015093831A (ja) | 2013-11-08 | 2015-05-18 | 日本メジフィジックス株式会社 | アルドステロン合成酵素阻害剤 |
JP2015093832A (ja) | 2013-11-08 | 2015-05-18 | 日本メジフィジックス株式会社 | 放射性ハロゲン標識化合物又はその塩、これを含む医薬 |
JP2015110563A (ja) | 2013-11-08 | 2015-06-18 | 日本メジフィジックス株式会社 | アルドステロン合成酵素阻害剤 |
JP2015093833A (ja) | 2013-11-08 | 2015-05-18 | 日本メジフィジックス株式会社 | 放射性ハロゲン標識化合物又はその塩、これを含む医薬 |
JP2015193545A (ja) | 2014-03-31 | 2015-11-05 | 国立大学法人京都大学 | 2−(3−ピリジニル)−1h−ベンズイミダゾール誘導体化合物、これを含む放射性医薬 |
JP6313098B2 (ja) | 2014-04-04 | 2018-04-18 | イーデーエム株式会社 | サーマルプリンタ |
-
2017
- 2017-06-09 CN CN201780035800.9A patent/CN109310787A/zh active Pending
- 2017-06-09 WO PCT/JP2017/021442 patent/WO2017213247A1/ja unknown
- 2017-06-09 CA CA3026617A patent/CA3026617A1/en not_active Abandoned
- 2017-06-09 KR KR1020187036667A patent/KR20190016971A/ko unknown
- 2017-06-09 AU AU2017278446A patent/AU2017278446A1/en not_active Abandoned
- 2017-06-09 US US16/308,014 patent/US20190255199A1/en not_active Abandoned
- 2017-06-09 JP JP2018521787A patent/JPWO2017213247A1/ja active Pending
- 2017-06-09 SG SG11201810847RA patent/SG11201810847RA/en unknown
- 2017-06-09 EP EP17810420.4A patent/EP3470091A4/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013512271A (ja) * | 2009-11-30 | 2013-04-11 | ノバルティス アーゲー | アルドステロン合成酵素阻害剤としてのイミダゾール誘導体 |
JP2014526539A (ja) * | 2011-09-23 | 2014-10-06 | エフ.ホフマン−ラ ロシュ アーゲー | 新規な二環式ジヒドロキノリン−2−オン誘導体 |
WO2015199205A1 (ja) * | 2014-06-26 | 2015-12-30 | 日本メジフィジックス株式会社 | 2-(3-ピリジニル)-1h-ベンゾイミダゾール誘導体化合物、及び、これを含む医薬 |
Non-Patent Citations (5)
Title |
---|
ABE TSUTOMU ET AL.: "A Novel CYP11B2-Specific Imaging Agent for Detection of Unilateral Subtypes of Primary Aldosteronism", J. CLIN. ENDOCRINOL. METAB., vol. 101, no. 3, March 2016 (2016-03-01), pages 1008 - 1015, XP055456963, ISSN: 0021-972X * |
KATADA JUN ET AL.: "Persistent Cardiac Aldosterone Synthesis in Angiotensin II Type 1A Receptor-Knockout Mice After Myocardial Infarction", CIRCULATION, vol. 111, no. 17, 2005, pages 2157 - 2164, XP055456972, ISSN: 0009-7322 * |
SATOH MAMORU ET AL.: "Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart", CLINICAL SCIENCE, vol. 102, 2002, pages 381 - 386, XP055562970, ISSN: 0143-5221 * |
VEERAVEEDU T. PUNNIYAKOTI ET AL.: "Comparative effects of torasemide and furosemide in rats with heart failure", BIOCHEMICAL PHARMACOLOGY, vol. 75, no. 3, 2008, pages 649 - 659, XP022418012, ISSN: 0006-2952 * |
VEERAVEEDU T. PUNNIYAKOTI ET AL.: "Torasemide, a long-acting loop diuretic, reduces the progression of myocarditis to dilated cardiomyopathy", EUROPEAN JOURNAL OF PHARMACOLOGY, vol. 581, no. 1-2, 2008, pages 121 - 131, XP022442578, ISSN: 0014-2999 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019131458A1 (ja) * | 2017-12-28 | 2019-07-04 | 日本メジフィジックス株式会社 | 2-[5-(イミダゾール-1-イルメチル)ピリジン-3-イル]ベンズイミダゾール誘導体化合物、及び、これを含む医薬 |
CN111527079A (zh) * | 2017-12-28 | 2020-08-11 | 日本医事物理股份有限公司 | 2-[5-(咪唑-1-基甲基)吡啶-3-基]苯并咪唑衍生物化合物及包含其的药物 |
JPWO2019131458A1 (ja) * | 2017-12-28 | 2021-05-13 | 日本メジフィジックス株式会社 | 2−[5−(イミダゾール−1−イルメチル)ピリジン−3−イル]ベンズイミダゾール誘導体化合物、及び、これを含む医薬 |
US11266753B2 (en) | 2017-12-28 | 2022-03-08 | Nihon Medi-Physics Co., Ltd. | 2-[5-(imidazol-1-ylmethyl)pyridin-3-yl]benzimtdazole derivative compound, and medicament including same |
JP7209970B2 (ja) | 2017-12-28 | 2023-01-23 | 日本メジフィジックス株式会社 | 2-[5-(イミダゾール-1-イルメチル)ピリジン-3-イル]ベンズイミダゾール誘導体化合物、及び、これを含む医薬 |
CN111527079B (zh) * | 2017-12-28 | 2023-08-11 | 日本医事物理股份有限公司 | 2-[5-(咪唑-1-基甲基)吡啶-3-基]苯并咪唑衍生物化合物及包含其的药物 |
WO2019216223A1 (ja) * | 2018-05-08 | 2019-11-14 | 日本メジフィジックス株式会社 | 心疾患の非侵襲的画像診断剤 |
Also Published As
Publication number | Publication date |
---|---|
US20190255199A1 (en) | 2019-08-22 |
CN109310787A (zh) | 2019-02-05 |
JPWO2017213247A1 (ja) | 2019-04-04 |
CA3026617A1 (en) | 2017-12-14 |
AU2017278446A1 (en) | 2018-12-20 |
EP3470091A4 (en) | 2019-06-19 |
SG11201810847RA (en) | 2019-01-30 |
EP3470091A1 (en) | 2019-04-17 |
KR20190016971A (ko) | 2019-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mateo et al. | Noninvasive assessment of hypoxia in rabbit advanced atherosclerosis using 18F-fluoromisonidazole positron emission tomographic imaging | |
EP2753605B1 (en) | Compositions, methods, and systems for the synthesis and use of imaging agents | |
Langen et al. | 3-[123I] Iodo-α-methyl-L-tyrosine: uptake mechanisms and clinical applications | |
Yao et al. | Infection imaging with 18F-FDS and first-in-human evaluation | |
US20210188784A1 (en) | 2-amino-2-(1,2,3-triazole-4-yl)propane-1,3-diol derivative of novel compound for directly inhibiting asm activity, and use thereof | |
JP6636921B2 (ja) | 2−(3−ピリジニル)−1h−ベンゾイミダゾール誘導体化合物、及び、これを含む医薬 | |
WO2017213247A1 (ja) | 心疾患の非侵襲的画像診断剤 | |
JP2012504131A5 (ja) | ||
Nie et al. | Imaging of hypoxia in mouse atherosclerotic plaques with 64Cu-ATSM | |
Mathijs et al. | A standardized method for in vivo mouse pancreas imaging and semiquantitative β cell mass measurement by dual isotope SPECT | |
Chen et al. | Cardiac peroxisome proliferator-activated receptor δ (PPARδ) as a new target for increased contractility without altering heart rate | |
JP2005523903A (ja) | アミロイド斑の生体内撮像用のベンゾチアゾール誘導体 | |
KR20120060943A (ko) | 지방산 대사 및 저장의 영상화를 위한 pet 방사성추적자 | |
L'Estrade et al. | Radiosynthesis and preclinical evaluation of [11C] Cimbi‐701–Towards the imaging of cerebral 5‐HT7 receptors | |
US9180212B2 (en) | β-amyloid plaque imaging agents | |
US9205156B2 (en) | Molecular imaging agents | |
Nakajima et al. | Pharmacokinetics of 3-[125I] iodo-α-methyl-l-tyrosine, a tumor imaging agent, after probenecid loading in mice implanted with colon cancer DLD-1 cells | |
JP6609868B2 (ja) | 放射性ハロゲン標識ピリド[1,2−a]ベンゾイミダゾール誘導体化合物 | |
WO2019216223A1 (ja) | 心疾患の非侵襲的画像診断剤 | |
L’Estrade et al. | Radiolabeling and in vivo evaluation of [11 C] AGH-44: a potential lead structure to develop a positron emission tomography radioligand for the 5-HT 7 receptor | |
US20180064742A1 (en) | Pet imaging tracer for imaging prostate cancer | |
US20230263915A1 (en) | Radiolabeled compounds | |
Gropler et al. | PET Imaging of Myocardial Metabolism in Health and Disease | |
WO2020045638A1 (ja) | 放射性イミダゾチアジアゾール誘導体化合物 | |
L’Estrade et al. | Development in ankylosing spondylitis has been suspended after the drug failed to show clinical benefit over methotrexate in a phase II trial. Menu |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018521787 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17810420 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3026617 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20187036667 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017278446 Country of ref document: AU Date of ref document: 20170609 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2017810420 Country of ref document: EP Effective date: 20190110 |